Venture Fund X, L.P.Atlas V... Net Worth

The estimated Net Worth of Venture Fund X, L.P.Atlas V... is at least $4.15 Milione dollars as of 19 July 2019. Venture V owns over 810,811 units of Magenta Therapeutics Inc stock worth over $3,897,102 and over the last 6 years Venture sold MGTA stock worth over $254,416.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Venture V MGTA stock SEC Form 4 insiders trading

Venture has made over 2 trades of the Magenta Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Venture bought 810,811 units of MGTA stock worth $15,000,004 on 19 July 2019.

The largest trade Venture's ever made was buying 810,811 units of Magenta Therapeutics Inc stock on 19 July 2019 worth over $15,000,004. On average, Venture trades about 206,264 units every 30 days since 2018. As of 19 July 2019 Venture still owns at least 5,567,289 units of Magenta Therapeutics Inc stock.

You can see the complete history of Venture V stock trades at the bottom of the page.

What's Venture V's mailing address?

Venture's mailing address filed with the SEC is 400 Technology Square, 400 Technology Square, Cambridge, MA 02139, USA.

Insiders trading at Magenta Therapeutics Inc

Over the last 6 years, insiders at Magenta Therapeutics Inc have traded over $6,775,591 worth of Magenta Therapeutics Inc stock and bought 1,257,000 units worth $10,105,000 . The most active insiders traders include Bruce Booth, Rock Ventures Iv, L.P.Third... e Jeffrey W. Albers. On average, Magenta Therapeutics Inc executives and independent directors trade stock every 46 days with the average trade being worth of $99,614. The most recent stock trade was executed by Rock Ventures Iv, L.P.Third... on 7 February 2023, trading 3,700,000 units of MGTA stock currently worth $3,071,000.

What does Magenta Therapeutics Inc do?

magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused on key areas of transplant medicine, magenta therapeutics is pioneering an integrated, but modular approach to stem cell therapies that reboot the blood and immune systems to create patient benefit. founded by internationally recognized leaders in stem cell transplant medicine, magenta therapeutics was launched in 2016 by third rock ventures and atlas venture and is headquartered in cambridge, mass. for more information, please visit www.magentatx.com.

Complete history of Venture V stock trades at AvroBio Inc e Magenta Therapeutics Inc

Magenta Therapeutics Inc executives and stock owners

Magenta Therapeutics Inc executives and other stock owners filed with the SEC include:

• Christina Isacson,
  Chief Business Officer
• Jason Gardner,
  President, Chief Executive Officer, Co-Founder, Director
• John Davis,
  Chief Medical Officer, Head of Research and Development
• Dr. Jason Gardner Ph.D.,
  Co-Founder, CEO, Pres & Director
• Stephen F. Mahoney J.D., MBA,
  Chief Financial & Operating Officer and Treasurer
• Anne McGeorge,
  Independent Director
• David Scadden,
  Independent Director
• Michael Bonney,
  Independent Chairman of the Board
• Alexis Borisy,
  Independent Director
• Jeffrey Albers,
  Independent Director
• Thomas Daniel,
  Independent Director
• Bruce Booth,
  Independent Director
• Blake Byers,
  Independent Director
• Amy Ronneberg,
  Independent Director
• Steve Mahoney,
  Chief Financial and Operating Officer
• Manisha Pai,
  Vice President - Communications and Investor Relations
• Zoran Zdraveski,
  Secretary and Chief Legal Officer
• Li Malmberg,
  Senior Vice President - Head of Manufacturing
• Kristen Stants,
  Chief People Officer
• Cindy Driscoll,
  Vice President - Finance
• Dr. Jan Pinkas Ph.D.,
  Sr. VP & Head of Translational Sciences
• Catherine Monaghan,
  Head of Clinical Devel. Operations
• Kristen Stants,
  Chief People Officer
• Lyndsey Scull,
  Director of Corp. Communications
• Thomas W. Beetham,
  Chief Legal Officer
• Jim Haney,
  Sr. Director of Investor Relations
• Dr. Lisa M. Olson Ph.D.,
  Head of Research & Chief Scientific Officer
• David Wayne Nichols,
  Chief Technical Officer
• Lisa Olson,
  See Remarks
• Caren Deardorf,
  Chief Commercial Officer
• Venture Fund X, L.P.Atlas V...,
  
• Rock Ventures Iv, L.P.Third...,
  
• 2016 Gp, L.L.C.Gv 2016 Gp, ...,
  
• Jason Ryan,
  See Remarks
• Venture Fund X, L.P. Atlas,
  10% owner
• Stephen F. Mahoney,
  See Remarks
• Michael P. Cooke,
  Chief Scientific Officer
• Thomas W. Beetham,
  See Remarks
• Jeffrey Humphrey,
  Chief Medical Officer
• Alison Frances Lawton,
  Director
• David Wayne Nichols,
  Chief Technical Officer
• Michael Vasconcelles,
  Director